Biosensor Boosts Disease Detection with Unmatched Sensitivity for 1-MNA

Kanazawa University researchers developed a biosensor with 700x greater sensitivity for detecting 1-MNA, enhancing disease diagnosis, drug discovery, and monitoring cancer and liver conditions.

FREMONT CA,: Researchers at the Nano Life Science Institute (WPI-NanoLSI) of Kanazawa University have unveiled an innovative biosensor that significantly enhances the detection of 1-methyl nicotinamide (1-MNA), a metabolite linked to various diseases, including cancer, metabolic disorders, and liver conditions. This innovation, published in Analytical Chemistry, represents a leap forward in disease diagnosis by offering improved sensitivity and accessibility compared to traditional methods like mass spectrometry and nuclear magnetic resonance (NMR).

Addressing Limitations of Traditional Detection Methods

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Metabolites such as 1-MNA, by-products of bodily processes, serve as critical biomarkers for diagnosing and monitoring diseases. Elevated levels of 1-MNA are associated with increased nicotinamide N-methyltransferase (NNMT) activity, a process linked to the progression of aggressive cancers and metabolic disorders. While effective, current detection methods rely on expensive equipment and complex sample preparation, limiting their use in routine clinical diagnostics.

Seeking a more efficient solution, researchers Masaya Ueno, Tomoki Ogoshi, and Atsushi Hirao explored pillararenes—a class of macrocyclic molecules known for their versatility in chemical sensing. By leveraging these molecules, the team developed a novel biosensor capable of detecting 1-MNA with significantly higher sensitivity and reduced complexity.

Enhanced Detection with Sulfonated Pillar [6]arene (P6AS)

In their latest work, the research team introduced a sulfonate-functionalized variant of pillar [6]arene (P6AS), which exhibits a binding affinity for 1-MNA that is 700 times greater than its predecessor, carboxylated pillar[6]arene (P6AC). This dramatic increase in sensitivity allows for detecting sub-micromolar concentrations of 1-MNA directly in unpurified urine samples.

Unlike earlier iterations, which required extensive sample purification and could not detect micromolar concentrations of 1-MNA in cell culture supernatants, the P6AS biosensor circumvents these limitations. It delivers precise results without complex preparation steps, making it a practical option for real-world diagnostic applications.

Potential Applications in Disease Diagnosis and Drug Development

The ability to measure 1-MNA levels accurately has profound clinical implications. Elevated NNMT activity is a hallmark of various cancers, and its suppression has shown promise in alleviating certain disease symptoms. By quantifying 1-MNA levels, healthcare providers can gain insights into NNMT activity, aiding in disease diagnosis and monitoring.

Moreover, the P6AS biosensor's high-throughput capabilities open new doors for drug discovery. The device's efficiency could expedite the screening of potential NNMT inhibitors, paving the way for novel treatments for diseases such as liver disease and cancer.

Despite its advantages, the biosensor does have limitations. While it performs well with urine samples, autofluorescence in human serum poses challenges for accurate detection. Researchers are optimistic that further refinements will address these issues, broadening the sensor’s applicability to more sample types.

Implications for Broader Healthcare Innovation

The improved sensitivity of the P6AS biosensor stems from the stronger acidity of its sulfonate groups compared to the carboxylate groups in earlier versions. This breakthrough not only enhances diagnostic precision but also has the potential to transform how diseases linked to NNMT activity are understood and treated.

“Monitoring NNMT expression and activity by quantifying 1-MNA is critical for elucidating patient pathology,” the researchers emphasized. They envision their biosensor as a tool for clinical diagnostics and advanced research, including in vivo imaging of cancer cells and high-throughput drug screening.

Future Directions and Optimism

While traditional methods like mass spectrometry remain the gold standard for detecting nanomolar concentrations, the accessibility and efficiency of the P6AS biosensor position it as a game-changer in diagnostic technology. The team believes that further refinement could unlock even greater potential, including applications in advanced imaging and real-time monitoring of disease progression.

“Further improvement of our strategy will contribute to high-throughput screening of NNMT inhibitors, diagnosis of liver diseases, and imaging of human cancer cells in vivo,” the researchers concluded.

This cutting-edge biosensor not only simplifies disease detection but also marks a significant step toward making diagnostic technologies more accessible. With its potential to improve diagnostics and treatment options, the P6AS biosensor promises to be a vital tool in the fight against cancer, liver disease, and other conditions linked to elevated 1-MNA levels.